Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Affymetrix and NuGEN Announce Agreement to Co-market the NuGEN WT-Ovation FFPE System
May 1st, 2007
Affymetrix Inc. (NASDAQ:AFFX) and NuGEN Technologies Inc., a privately held company that develops and commercializes nucleic acid amplification and labeling systems for small and difficult samples, announced their agreement to co-market a solution that enables researchers to access FFPE (formalin-fixed, paraffin-embedded) tissue samples derived from years of clinical studies previously inaccessible by traditional RNA amplification methods. The NuGEN WT-Ovation(TM) FFPE System provides scientists the opportunity to conduct global gene expression analysis on their vast archives of small and degraded FFPE samples, using standard Affymetrix GeneChip(R) 3' expression arrays. ...
Source: Cancer Weekly (2007-05-01)
|
|
Advertisement |
|
|
|
